

Title (en)

ISOLATED CHIMERIC ANTIGEN RECEPTOR, MODIFIED T CELL COMPRISING SAME AND USE THEREOF

Title (de)

ISOLIERTER CHIMÄRER ANTIGEN-REZEPTOR, DIESE ENTHALTENDE MODIFIZIERTE T-ZELLE UND DEREN VERWENDUNG

Title (fr)

RÉCEPTEUR ANTIGÉNIQUE CHIMÉRIQUE ISOLÉ, LYMPHOCYTE T MODIFIÉ LE COMPRENANT ET UTILISATION ASSOCIÉE

Publication

EP 3757133 A4 20211201 (EN)

Application

EP 19751451 A 20190201

Priority

- CN 201810140396 A 20180211
- CN 2019074392 W 20190201

Abstract (en)

[origin: EP3757133A1] An isolated CD19-binding chimeric antigen receptor, a CRISPR-Cas9 system-based method for knocking out TRAC, B2M and PD-1 genes in T cells in vitro, crRNA used in the method, gene knockout T cells obtained according to the method, and a use thereof.

IPC 8 full level

C07K 19/00 (2006.01); **A61P 35/00** (2006.01); **C12N 15/113** (2010.01)

CPC (source: EP US)

A61K 39/4611 (2023.05 - EP US); **A61K 39/4631** (2023.05 - EP US); **A61K 39/464412** (2023.05 - EP US); **A61K 2239/38** (2023.05 - US); **A61K 2239/48** (2023.05 - US); **A61P 35/00** (2018.01 - EP US); **C07K 14/7051** (2013.01 - EP US); **C12N 5/0636** (2013.01 - US); **C12N 9/22** (2013.01 - US); **C12N 15/1138** (2013.01 - EP); **C12N 15/63** (2013.01 - US); **A61K 2239/38** (2023.05 - EP); **A61K 2239/48** (2023.05 - EP); **C07K 2319/02** (2013.01 - US); **C07K 2319/03** (2013.01 - EP US); **C12N 2310/20** (2017.05 - EP US)

Citation (search report)

- [XY] WO 2017216562 A1 20171221 - AUTOLUS LTD [GB]
- [Y] WO 2017172981 A2 20171005 - UNIV SOUTHERN CALIFORNIA [US]
- [Y] WO 2017181119 A2 20171019 - NOVARTIS AG [CH], et al
- [Y] WO 2016139487 A1 20160909 - UCL BUSINESS PLC [GB]
- [Y] WO 2018014039 A1 20180118 - POSEIDA THERAPEUTICS INC [US], et al
- [E] WO 2020088631 A1 20200507 - GRACELL BIOTECHNOLOGIES SHANGHAI CO LTD [CN], et al
- [Y] LEVI J. RUPP ET AL: "CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells", SCIENTIFIC REPORTS, vol. 7, no. 1, 7 April 2017 (2017-04-07), XP055387393, DOI: 10.1038/s41598-017-00462-8
- [T] SALAS-MCKEE JANUARY ET AL: "CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy", HUMAN VACCINES & IMMUNOTHERAPEUTICS, vol. 15, no. 5, 4 May 2019 (2019-05-04) - 2 April 2019 (2019-04-02), US, pages 1126 - 1132, XP055851526, ISSN: 2164-5515, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605860/pdf/khvi-15-05-1571893.pdf> DOI: 10.1080/21645515.2019.1571893
- See also references of WO 2019154313A1

Cited by

EP3650545A4

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

EP 3757133 A1 20201230; EP 3757133 A4 20211201; CN 111094358 A 20200501; TW 201934575 A 20190901; US 2023183313 A1 20230615; WO 2019154313 A1 20190815

DOCDB simple family (application)

EP 19751451 A 20190201; CN 2019074392 W 20190201; CN 201980004475 A 20190201; TW 108104188 A 20190201; US 201916967294 A 20190201